Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-14
DOI
10.1038/s41467-020-18442-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
- (2019) Rashmi R. Shah et al. DRUG SAFETY
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
- (2019) Elizabeth J. Adams et al. NATURE
- Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
- (2019) Abhijit Parolia et al. NATURE
- Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
- (2019) Kenji Kita et al. CANCER SCIENCE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- ChIP‐Atlas: a data‐mining suite powered by full integration of public ChIP‐seq data
- (2018) Shinya Oki et al. EMBO REPORTS
- Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
- (2017) Chao-Chi Ho et al. Journal of Thoracic Oncology
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
- (2017) Shinji Kohsaka et al. Science Translational Medicine
- Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
- (2017) Aaron Simpson et al. Targeted Oncology
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- Differential Roles of Insulin and IGF-1 Receptors in Adipose Tissue Development and Function
- (2016) Jeremie Boucher et al. DIABETES
- Essential Role of IGFIR in the Onset of Male Brown Fat Thermogenic Function: Regulation of Glucose Homeostasis by Differential Organ-Specific Insulin Sensitivity
- (2016) Vanesa Viana-Huete et al. ENDOCRINOLOGY
- MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines
- (2016) Minoru Terashima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nucleation of DNA repair factors by FOXA1 links DNA demethylation to transcriptional pioneering
- (2016) Yu Zhang et al. NATURE GENETICS
- Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
- (2016) H. Kitai et al. Cancer Discovery
- Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis
- (2015) Chee Khoon Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
- (2015) Martin Fassnacht et al. LANCET ONCOLOGY
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- Tumor heterogeneity in the clinic: is it a real problem?
- (2013) Filip Janku Therapeutic Advances in Medical Oncology
- Cancer genetics and genomics of human FOX family genes
- (2012) Masuko Katoh et al. CANCER LETTERS
- Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
- (2012) A. B. Cortot et al. CANCER RESEARCH
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization
- (2012) Jesse D. Ziebarth et al. NUCLEIC ACIDS RESEARCH
- Pioneer transcription factors: establishing competence for gene expression
- (2011) K. S. Zaret et al. GENES & DEVELOPMENT
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
- (2009) Mark J Mulvihill et al. Future Medicinal Chemistry
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started